- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07951216
Role of Uremic Toxins in Mild Cognitive Impairment in Chronic Kidney Disease (MOMENTUM)
Investigator-initiated, Multicentre, International, Cross-sectional and Longitudinal Clinical Study Elucidating the Pathophysiology of Mild Cognitive Impairment in Chronic Kidney Disease With a Focus on the Role of Uremic Toxins
MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.
The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Comportamental: MoCA Test
- Teste de diagnostico: Laboratory tests
- Teste de diagnostico: Non-contrast-enhanced brain MRI
- Comportamental: Comprehensive neuropsychological test battery
- Comportamental: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section
- Comportamental: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections
- Comportamental: Questionnaires
- Comportamental: New MCI-CKD QoL Questionnaire
Descrição detalhada
Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.
Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.
Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.
As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.
Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.
The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Matias Trillini, M.D.
- Número de telefone: +390354535411
- E-mail: matias.trillini@marionegri.it
Locais de estudo
-
-
-
Pamplona, Espanha, 31008
- Clínica Universidad de Navarra
-
Contato:
- Nuria Garcia Fernandez, MD PhD
- Número de telefone: +34948255400
- E-mail: nrgarcia@unav.es
-
-
-
-
-
Naples, Itália, 80131
- AOU University of Campania "Luigi Vanvitelli"
-
Contato:
- Alessandra Perna
- Número de telefone: +390815666822
- E-mail: alessandra.perna@unicampania.it
-
-
BG
-
Ranica, BG, Itália, 24020
- Clinical Research Centre for Rare Diseases Aldo e Cele Daccò
-
Contato:
- Matias Trillini, M.D.
- Número de telefone: +390354535411
- E-mail: matias.trillini@marionegri.it
-
-
-
-
-
Derby, Reino Unido, DE22 3NE
- University Hospitals of Derby and Burton NHS Foundation Trust
-
Contato:
- Nicholas Selby
- Número de telefone: +44(0)1332724665
- E-mail: nicholas.selby@nottingham.ac.uk
-
-
-
-
-
Lausanne, Suíça, 1005
- Centre Hospitalier Universitaire Vaudois
-
Contato:
- Menno Pruijm, Prof.
- Número de telefone: +41(0)213141131
- E-mail: Menno.Pruijm@chuv.ch
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria
- Male or female aged 40-75 years at time of screening;
- Availability for longitudinal follow-up;
- Signed informed consent
Specifically for CKD participants:
- CKD stage G3a/G3b, or stage G4-G5 without kidney replacement therapy, or stage G5 undergoing hemodialysis (HD) for more than 3 months;
- MoCA score in the range [18-25];41
Specifically for controls:
-
Normal renal function:
- For controls aged < 65 years, eGFR ≥ 90 mL/min/1.73 m2;
- For controls aged ≥ 65 years, eGFR ≥ 60 mL/min/1.73 m2.
-
No detectable proteinuria at screening (negative urine dipstick);
-
MoCA score ≥ 26/30.
Exclusion Criteria
- Contraindication to MRI including claustrophobia, pregnancy or breastfeeding, cardiac pacemakers, aneurysm clips, or other MRI-incompatible devices, or inability to undergo MRI;
- Pre-existing neurological disorders known to affect cognitive function (e.g., dementia, Parkinson's disease, multiple sclerosis, epilepsy or neurodegenerative disorders);
- History of ischemic or hemorrhagic stroke and/or previous brain surgery;
- History of severe traumatic brain injury;
- Treated or untreated clinically significant depressive disorder that, in the investigator's judgment, may interfere with cognitive assessment;
- Recent hospitalization for acute events within the last 3 months, except for percutaneous transluminal angioplasty (PTA) of fistula, catheter replacement and elective hospitalizations;
- Serious acute illness within the last 3 months;
- Active solid tumors with or without metastasis;
- Inflammatory bowel disease;
- Systemic corticosteroid treatment for > 6 months at a prednisone-equivalent dose > 10 mg/day;
- Planned pregnancy during the 18-month follow-up period;
Specifically for CKD patients:
- Peritoneal dialysis;
- Kidney transplantation at enrolment;
Specifically for controls:
● Any chronic clinically significant condition, except for hypertension treated with < 3 antihypertensive drugs.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Group 1
Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimental: Group 2
Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR < 30 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimental: Group 3
Patients with CKD stage G5 on chronic hemodialysis (eGFR < 15 mL/min/1.73 m2) |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Sections specific to kidney disease excluding the first section Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project |
|
Experimental: Group 4
Healthy controls |
Montreal Cognitive Assessment Test The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI) The comprehensive battery of neuropsychological tests includes: Episodic memory [assessed through Rey Auditory Verbal Learning Test (RAVLT)]; Processing speed and executive function [assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)]; Processing speed, attention, and working memory [assessed through Symbol Digit Modalities Test (SDMT)]; Language and executive function [assessed through Verbal Fluency Test (VFT))] Executive function assessed through Frontal Assessment Battery (FAB)] "Your Health" section, corresponding to the SF-12 questionnaire Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
Prazo: Baseline (Visit 2, Day 0)
|
Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately. |
Baseline (Visit 2, Day 0)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Norberto Perico, M.D., Istituto Di Ricerche Farmacologiche Mario Negri
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Transtornos Mentais, Desordem Mental
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Distúrbios Neurocognitivos
- Distúrbios Cognitivos
- Insuficiência renal
- Condições Patológicas, Sinais e Sintomas
- Disfunção cognitiva
- Insuficiência Renal Crônica
- Qualidade, acesso e avaliação da assistência médica
- Técnicas de investigação
- Métodos epidemiológicos
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Coleta de dados
- Mecanismos de avaliação de saúde
- Qualidade de assistência médica
- Saúde pública
- Meio ambiente e saúde pública
- Pesquisas e questionários
- Técnicas de laboratório clínico
Outros números de identificação do estudo
- MOMENTUM
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .